Nivolumab Scores in Bladder and Renal Cancer Trials

Providing adjuvant nivolumab after radical resection continues to yield clinically meaningful disease-free survival ...

APRIL 16, 2025

FDA Approves Opdivo Qvantig for Subcutaneous Injection

The FDA approved nivolumab plus hyaluronidase-nvhy (Opdivo Qvantig, Bristol Myers Squibb) for subcutaneous ...

DECEMBER 30, 2024

Subcutaneous Injection of Nivolumab on the Horizon

Patients and clinicians may have an injectable form of the immunotherapy nivolumab (Opdivo, Bristol Myers Squibb) ...

MARCH 29, 2024

Welireg Approved for Advanced Renal Cell Carcinoma

The FDA approved belzutifan (Welireg, Merck) for patients with advanced renal cell carcinoma (RCC) following a ...

DECEMBER 15, 2023

Study Reports Long-Term Data for Nivolumab Plus Cabozantinib in Advanced RCC

Nivolumab plus cabozantinib outperforms sunitinib for first-line treatment of advanced clear cell renal cell ...

MARCH 22, 2023

Double Checkpoint Inhibitors Plus TKI Improves Control of RCC

In patients with advanced renal cell carcinoma, the addition of the tyrosine kinase inhibitor cabozantinib ...

OCTOBER 3, 2022

Adjuvant Pembrolizumab Continues to Improve DFS in High-Risk RCC

An updated analysis of the phase 3 KEYNOTE-564 study demonstrates that adjuvant pembrolizumab continued to show a ...

JUNE 10, 2022

Keytruda Gains Approval to Treat Patients With RCC After Nephrectomy

The FDA approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of patients with renal cell carcinoma ...

NOVEMBER 29, 2021

Lenvima Plus Keytruda Approved for First-Line Treatment of Advanced RCC

The FDA approved the combination of lenvatinib (Lenvima, Eisai) plus pembrolizumab (Keytruda, Merck) for first-line ...

AUGUST 16, 2021

FDA Approves Tivozanib for Adult Patients With Relapsed or Refractory Advanced RCC

The FDA approved tivozanib (Fotivda, AVEO Oncology) for the treatment of adults with relapsed or refractory ...

MARCH 12, 2021

FDA Approves Nivolumab-Cabozantinib as First-Line Treatment of Advanced RCC

The FDA approved nivolumab in combination with cabozantinib for the first-line treatment of patients with advanced ...

FEBRUARY 15, 2021

CheckMate 9ER Trial: ICI Provides Survival Benefit in Renal Cell Carcinoma

Relative to the previous standard of sunitinib, a combination of the checkpoint inhibitor nivolumab and the ...

DECEMBER 4, 2020